Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Chengpei ZhuHu LiXiaobo YangShanshan WangYunchao WangNan ZhangYanyu WangJingnan XueLonghao ZhangCong NingXu YangZiyu XunJiashuo ChaoJunyu LongXin-Ting SangZhenyu ZhuHaitao ZhaoPublished in: Cancer immunology, immunotherapy : CII (2023)
PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy represent an effective and tolerable regimen for advanced ICC in a multicenter retrospective real-world study. TBS, TNM stage, and PD-L1 expression can be used as potential prognostic factors for OS and PFS.